Overactive bladder (OAB) syndrome is a chronic medical condition which has a major influence on the quality of life in a significant amount of the population. OAB affects performance of daily activities and has an estimated prevalence of 16.5%. Many sufferers do not seek medical help. Moreover, many family physicians and even gynecologists are not familiar with this issue. Usually patients suffer from OAB in advanced age. Nocturia is reported as the most bothersome symptom in the elderly population. The aim of our review was to discuss all aspects of this challenging disorder and suggest tools for assessment and management strategies. Practitioners can easily overlook urinary complains if they not directly queried. We would like to encourage practitioners to give more attention to this issue.

Keywords:
Overactive bladder syndrome, Antimuscarinic drugs, Overactive detrusor muscle, Nocturia, Aging
1.
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ: Prevalence and burden of over-active bladder in the United States. World J Urol 2003;20:327-336.
2.
Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN: An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20.
3.
Van Dijk MM, Wijkstra H, Debruyne FM, De La Rosette JJ, Michel MC: The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int 2010;105: 1141-1146.
4.
Middelkoop HA, Smilde-van den Doel DA, Neven AK, Kamphuisen HA, Springer CP: Subjective sleep characteristics of 1,485 males and females aged 50-93: effects of sex and age, and factors related to self-evaluated quality of sleep. J Gerontol A Biol Sci Med Sci 1996;51:M108-115.
5.
van der Vaart CH, Roovers JP, de Leeuw JR, Heintz AP: Association between urogenital symptoms and depression in community -dwelling women aged 20 to 70 years. Urology 2007;69:691-696.
6.
Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD: The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 2009;15(suppl 4):S90-97.
7.
Marinkovic SP, Rovner ES, Moldwin RM, Stanton SL, Gillen LM, Marinkovic CM: The management of overactive bladder syndrome. BMJ 2012;344:e2365.
8.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-766.
9.
de Groat WC: A neurologic basis for the overactive bladder. Urology 1997;50(6A suppl):36-52.
10.
Brading AF: Spontaneous activity of lower urinary tract smooth muscles: correlation between ion channels and tissue function. J Physiol 2006;570:13-22.
11.
Drake MJ, Mills IW, Gillespie JI: Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 2001;358:401-403.
12.
Andersson KE: Detrusor myocyte activity and afferent signaling. Neurourol Urodyn 2010;29:97-106.
13.
Wein AJ, Rackley RR: Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol 2006;175: S5-10.
14.
Steele AC, Kohli N, Mallipeddi P, Karram M: Pharmacologic causes of female incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:106-110.
15.
Borrie MJ, Campbell K, Arcese ZA, Bray J, Hart P, Labate T, Hesch P: Urinary retention in patients in a geriatric rehabilitation unit: prevalence, risk factors, and validity of bladder scan evaluation. Rehabil Nurs 2001; 26:187-191.
16.
Locher JL, Goode PS, Roth DL, Worrell RL, Burgio KL: Reliability assessment of the bladder diary for urinary incontinence in older women. J Gerontol A Biol Sci Med Sci 2001;56:M32-35.
17.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49.
18.
Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr, Scarpero HM, Tessier CD, Vasavada SP: Diagnosis and treatment of over-active bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188(6 suppl):2455-2463.
19.
Haylen BT, Ashby D, Sutherst JR, Frazer MI, West CR: Maximum and average urine flow rates in normal male and female. populations - the Liverpool nomograms. Br J Urol 1989; 64:30-38.
20.
Al Afraa T, Mahfouz W, Campeau L, Corcos J: Normal lower urinary tract assessment in women: I. Uroflowmetry and post-void residual, pad tests, and bladder diaries. Int Urogynecol J 2012;23:681-685.
21.
Thuroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, Hampel C, Neisius A, Schröder A, Tubaro A: EAU Guidelines on Urinary Incontinence. Actas Urol Esp 2011;35:373-388.
22.
Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, Kakizaki H, Obara K, Gotoh M, Igawa Y, Seki N, Yoshida M: Clinical guidelines for overactive bladder. Int J Urol 2009;16:126-142.
23.
Hashim H, Abrams P: How should patients with an overactive bladder manipulate their fluid intake? BJU Int 2008;102:62-66.
24.
Lohsiriwat S, Hirunsai M, Chaiyaprasithi B: Effect of caffeine on bladder function in patients with overactive bladder symptoms. Urol Ann 2011;3:14-18.
25.
Shafik A, Shafik IA: Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol 2003;20:374-377.
26.
Burgio KL, Locher JL, Goode PS: Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000;48:370-374.
27.
Robinson D, Cardozo L: Antimuscarinic drugs to treat overactive bladder. BMJ 2012; 344:e2130.
28.
Herbison P, Hay-Smith J, Ellis G, Moore K: Effectiveness of anticholinergic drugs compared with placebo in the treatment of over-active bladder: systematic review. BMJ 2003; 326:841-844.
29.
Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; CD003781.
30.
Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D: The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-562.
31.
Lee S, Malhotra B, Creanga D, Carlsson M, Glue P: A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol 2009;9:55.
32.
Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL: Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med 2012;156:861-874.
33.
Peeker R, Samsioe G, Kowalski J, Andersson AS, Bergqvist A: A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden. Scand J Urol Nephrol 2010;44:138-146.
34.
Oefelein MG: Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 2011; 34:733-754.
35.
Rosenberg MT, Newman DK, Tallman CT, Page SA: Overactive bladder: recognition requires vigilance for symptoms. Cleve Clin J Med 2007;74(Suppl 3):S21-29.
36.
Olshansky B, Ebinger U, Brum J, Egermark M, Viegas A, Rekeda L: Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. J Cardiovasc Pharmacol Ther 2008;13:241-251.
37.
Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464- 470.
38.
Sexton CC, Notte SM, Maroulis C, Dmo-chowski RR, Cardozo L, Subramanian D, Coyne KS: Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011; 65:567-585.
39.
Chapple C, Khullar V, Gabriel Z, Dooley JA: The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5-26.
40.
Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, Roach M, Miklos J, Saltzstein D, Boone T, Staskin DR, Albrecht D: Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358-363.
41.
Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57: 414-421.
42.
Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, Kell SH: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78:687-695.
43.
Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J: Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010;105:58-66.
44.
Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006;176: 177-185.
45.
Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A: Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012;61:834- 839.
46.
Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C: OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013;64:249-256.
47.
US Food and Drug Administration. FDA Approves Botox To Treat Overactive Bladder. Jan 18 2013; Accessed Apr 9 2013. Available at http://www.fda.gov/NewsEvents/News-room/PressAnnouncements/ucm336101.htm.
48.
Ridout AE, Yoong W: Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy. J Obstet Gynaecol 2010;30:111-114.
49.
Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, van Kerrebroeck PE: Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol 1999;162:352-357.
50.
van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama á Nijholt AA, Siegel S, Jonas U, Fowler CJ, Fall M, Gajewski JB, Hassouna MM, Cappellano F, Elhilali MM, Milam DF, Das AK, Dijkema HE, van den Hombergh U: Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178:2029-2034.
51.
Mast P, Hoebeke P, Wyndaele JJ, Oosterlinck W, Everaert K: Experience with augmentation cystoplasty. A review. Paraplegia 1995; 33:560-564.
52.
Holm J, Struckmann JR, Frimodt-Moller C: Augmentation ile-ocystoplasty in women with disabling urge incontinence. Ugeskr Laeger 1995;157:1528-1530.
53.
Somani BK, Kumar V, Wong S, Pickard R, Ramsay C, Nabi G, Grant A, N'Dow J: Bowel dysfunction after transposition of intestinal segments into the urinary tract: 8-year prospective cohort. J Urol 2007;177:1793-1798.
54.
Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C: Efficacy and tolerability of mirabegron, aβ (3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283-295.
55.
Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z: Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014; 65:755-765.
56.
Andersson KE: New pharmacologic targets for the treatment of the overactive bladder: an update. Urology 2004;63(3 suppl 1):32-41.
57.
Chancellor MB: New frontiers in the treatment of overactive bladder and incontinence. Rev Urol 2002;4(Suppl 4):S50-56.
58.
Epstein BJ, Gums JG, Molina E: Newer agents for the management of overactive bladder. Am Fam Physician 2006;74:2061- 2068.
59.
Ng CK, Gonzalez RR, Te AE: Refractory overactive bladder in men: update on novel therapies. Curr Urol Rep 2006;7:456-461.
© 2017 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.